Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males

Trial Profile

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Dec 2016

At a glance

  • Drugs ODM 106 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions
  • Acronyms FIMPAM
  • Sponsors Orion
  • Most Recent Events

    • 02 Feb 2016 According to an Orion media release, status changed from recruiting to discontinued.
    • 14 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 14 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top